Drug Profile
Denosumab biosimilar - Intas Pharmaceuticals
Latest Information Update: 20 Jun 2022
Price :
$50
*
At a glance
- Originator Intas Pharmaceuticals
- Class Antihypercalcaemics; Antineoplastics; Antirheumatics; Calcium regulators; Immunotherapies; Monoclonal antibodies; Osteoporosis therapies
- Mechanism of Action Antibody-dependent cell cytotoxicity; RANK ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Registered Osteoporosis; Postmenopausal osteoporosis
Most Recent Events
- 11 Nov 2021 Intas Pharmaceutical initiates enrolment in a phase III trial for Osteoporosis and Postmenopausal osteoporosis in India (SC) (NCT05419427)
- 15 Oct 2020 Intas Pharmaceuticals plans a phase I trial in healthy volunteers in India (CTRI2020-09-027619),
- 25 Sep 2019 Intas Pharmaceuticals plans a phase III trial in Solid tumours (with bone metastases) in India (CTRI/2019/01/017364)